ClinicalTrials.gg
CompletedNCT06691828Updated Mar 12, 2025

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

A Phase 1 interventional study of NX-5948 in Healthy Volunteer, sponsored by Nurix Therapeutics, Inc.. Completed at 1 site in United States. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Nurix Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of [14C]-NX-5948. Period 1 will analyze PD (pharmacodynamics) and exploratory biomarkers. Period 2 will analyze total radioactivity and metabolite profiling.

Read the detailed description

In Period 1 all subjects will receive a single dose of NX-5948 by IV and undergo pre and post dose labs to assess PK (pharmacokinetics) and PD parameters.

In Period 2 all subjects will receive a single dose of NX-5948 by mouth. Pre and post dose blood, urine, and feces will be collected until NX-5948 is no longer identified in samples.

Periods 1 and 2: Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Nurix Therapeutics, Inc. is the lead sponsor of 10 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study:

  • Healthy, adult, male, 18-55 years of age
  • Subjects must follow protocol-specified guidance as described in the protocol.
  • Continuous non-smoker who has not used nicotine-and tobacco-containing products for at least 3 months prior to the first dosing based on subject self-reporting.
  • (BMI) ≥ 18.0 and ≤ 30.0 kg/m2 at the screening visit.
  • Medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, and 12-lead safety ECGs, at the screening visit and/or first check-in, as deemed by the PI or designee,
  • Understands the study procedures in the form (ICF) and be willing and able to comply with the protocol.

Key Exclusion Criteria:

Subjects must not be enrolled in the study if they meet any of the following criteria:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • Clinically significant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neoplastic (including leukemia, lymphoma, malignant melanoma), myeloproliferative, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders, or any illness that, in the opinion of the PI or designee, might confound the results of the study or pose an additional risk to the subjects by their participation in the study.
  • History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
  • History or presence of , angioedema, or idiosyncratic reaction to the study drug(s) or related compounds.
  • History or presence of:

    • Significant multiple and/or severe allergies, including anaphylactic reaction.
    • Personal or family history of prolonged syndrome or family history of sudden cardiac death.
    • Evidence of atrial fibrillation, atrial flutter, complete bundle branch block, Wolff-Parkinson-White Syndrome, or cardiac pacemaker.
    • Adrenal insufficiency.
    • Skin infection.
    • Any significant (as determined by the PI) drug-related allergic reactions such as, anaphylaxis, Stevens-Johnson syndrome, urticaria or multiple drug allergies.
  • Has tattoo(s) or scarring at or near the site of IV injection or any other condition which may interfere with IV injection site examination, in the opinion of the PI or designee.
  • Previous exposure to NX-5948.
  • Any significant acute illness within 30 days prior to first dosing.
  • Regular alcohol consumption > 14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) prior to first dosing.
  • Positive urine drug or alcohol results at the screening visit or first check in.
  • Positive Coronavirus disease 2019 (COVID-19) results at first check-in.
  • Positive results for (HIV), surface antigen (HBsAg), or virus (HCV) at the screening visit.
  • Has received radiolabeled substances or has been exposed to radiation sources over the past 12 months or is likely to receive radiation exposure or radioisotopes within the next 12 months such that participation in this study would increase their total exposure beyond the recommended levels considered safe (i.e., weighted annual limit recommended by the FDA 21CFR361 of 5000 mrem).
  • Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Active Treatment Arm IV and Oral

    This single Arm will include a single dose by IV and a single dose given by mouth for all 8 subjects.

    Drug: NX-5948

Interventions

  • NX-5948 will be given once by IV and then given once by mouth.

06

What researchers measure

Primary outcomes

  1. Characterize Area Under the Curve (AUC0-inf), Half-life (T1/2) after IV dosing of NX-5948

    Characterize the Area Under the Curve (AUC0-inf), Half-life (T1/2) of a single IV dose of NX-5948 in healthy adult male subjects.

    Time frame: 9 weeks

  2. Evaluation of metabolite after oral dosing with [14C]-NX-5948

    Identify major metabolite and its AUC in plasma following a single oral dose of \[14C\]-NX-5948 in healthy adult male subjects.

    Time frame: 9 weeks

  3. Assessment of bioavailability with oral dosing of NX-5948

    Determine the absolute bioavailability (ABA) of an oral formulation of \[NX-5948C\]- in healthy adult male subjects.

    Time frame: 9 weeks

  4. Assessment of total radioactivity after oral dosing with NX-5948

    Determine the recovery of total radioactivity (TRA; mass balance) as a percentage of the administered dose after a single oral dose of \[14C\]-NX-5948 in healthy adult male subjects.

    Time frame: 9 weeks

  5. Assessment of whole blood to plasma ratio for TRA after oral dosing with NX-5948

    Characterize whole blood to plasma ratio for TRA following a single oral dose of \[14C\]-NX-5948 in healthy adult male subjects (i.e., whole blood:plasma partitioning ratio).

    Time frame: 9 weeks

  6. Characterize the Clearance (CL) after IV dosing of NX-5948

    Character the Clearance (CL) after IV dosing of NX-5948in healthy adults male subjects.

    Time frame: 9 weeks

  7. Characterize the Volume of distribution (Vz) after IV dosing of NX-5948

    Character the Volume of distribution (Vz) after IV dosing of NX-5948in healthy adults male subjects.

    Time frame: 9 weeks

07

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Nov 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 15, 2024
StartActual
Nov 1, 2024
Primary completionActual
Nov 28, 2024
CompletionActual
Dec 5, 2024
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06691828
Lead sponsor
Nurix Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 15, 2024
Start date
Nov 1, 2024
Primary completion
Nov 28, 2024
Completion
Dec 5, 2024
Last update
Mar 12, 2025

Study contacts

Sarah Injac, MD PhD
study director · Nurix Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NX-5948

Start the discussion